All In MedTech

FDA Clearance Tracker · DEN210027

The Cooral System

A De Novo grant creates a new device type for a low to moderate risk device with nothing on the market to compare it to. Later devices of this type can use it as their comparison in a 510(k).

Last checked: Nov 20, 2026Latest source record: Oct 14, 2022 (this decision)Source: openFDAMethods & limitations

De NovoNew device typeBreakthrough

Decided

Oct 14, 2022

De Novo granted

Time to decision

469 days

Received Jul 2, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

De Novo

Direct

Device class

Class II

The decision

FDA number
DEN210027
Device name
The Cooral System
Applicant
Braincool AB
Applicant location
Lund, SE
Received
Jul 2, 2021
Decided
Oct 14, 2022
Decision
De Novo granted
Submission type
Direct

Device type

Device class
Class II
Regulation
21 CFR 872.5590

Every decision under product code QUA

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Braincool AB

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.